As a key metabolic regulator, p53 facilitates the transition from glycolysis to mitochondrial metabolism, enhances iron‐sulfur (Fe‐S) cluster biosynthesis, and regulates the levels of the copper chelator GSH.[41] Elesclomol, an exogenous copper ionophore, was discontinued in Phase III clinical trials for melanoma treatment; however, it has shown effectiveness in patients with lower plasma lactate dehydrogenase levels. Here, TP53 is linked to melanoma.